Mission: Break the Mouse Lifespan World Record by 2.5X, implement in humans immediately

Project MouseSpan

Number of mouse lifespan studies in the world



Number of combo-therapy studies to date: 10
Yet combo studies outperform

Combination outperforms either alone	% gain in max lifespan vs monotherapy*
3 x anti-growth mutations + CRON	+21% to + 51%
6 Telomerase gene therapies vs 1	+20%
6 Follistatin gene therapies vs 1	+20%
CRON + Growth Hormone mutations	+20%
20 x Placental Stem Cell IVs vs 1	+25%
20 x baby plasma exosome IVs vs 1	+20%
Rapa + Acarbose	+10%
Rapa + Metformin	+10%
Rapa + Trametinib	+10%
NAC + Glycine	+20%

Current record = 41%*
Target: 100% max lifespan increase

Mouse Lifespan Leaderboard

Hover over an Intervention name for more details.

#		INTERVENTION	HUMAN AGE EQUIVALENT START	AVG LIFESPAN INCREASE	MAX LIFESPAN INCREASE
1	CR	Caloric restriction 25% human equivalent	45	62%	54%
2	6X	6 x Telomerase Gene Therapy IV (CMV) Read Study	55	41%	41%
3	2X	20 x PDA-001 Placental Stem Cells IV	30	21%	32%
4	6X	6 x Follistatin Gene Therapy IV	55	33%	29%
5	N+	NAC + Glycine 1.2g each	46	24%	25%
6	9M	9 mg Rapamycin/wk + up to 600 mg acarbose/d	28	37%	24%

Leadership

Dr. Oliver Zolman

Lead Investigator

Creator of Longevity School, Project Blueprint, and the field of Competitive Rejuvenation in 2018

Dr. Patrick Sewell

Research Lead

Human Telomere Rejuvenation world record holder, Inventor of Cancer Cryoablation, World's most experienced rejuvenation gene therapy medical doctor

Roadmap

$11M USD

For Profit or Philanthropy (funding sought)

10,000 mice

age 70 human equivalent

300 combinations

of therapies

Spin-out winning therapies

in biotechs, clinics & $101M Healthspan XPRIZE

Revenue

1. Innovation steps → Run mouse studies → Patent → Sell direct to consumer + clinicians + pet rejuvenation + license
2. Unique ageing dataset for pharma AI
3. R&D Credits/follow-on grants
4. Pharma M&A

Spending in 3 years

- 10,000 mice + tests approx. $5-6M
- Therapies manufacturing: approx. $4M (gene and cell highest cost)
- Marketing, staff, patents: approx. $3M

Corporation

MouseSpan is a project run by NewCo Triple Helix Research (50:50 Zolman:Patrick), a subsidiary of Triple Helix Mexico (THM) Group.

THM Group (Patrick’s company) has $1-1.5m monthly revenue, no debt, no investors, cash +ve, estimated ARR of $40m by Dec 2025.

Example of one of our gene therapies discovered via mouse work

Single IV injection TripleHelix AAV9 Follistatin Gene Therapy

+ 7.2 kg muscle (+15.8 lbs) (+10% muscle as % of total body mass) (DEXA)

Note: my frame is small for my organs (?) hence the bowed appearance (?pectus carinatum)

Body weights
Before: 78.5kg (173 lbs)
After: 78.5 kg (173 lbs)

No TRT/other confounds

Roadmap

1500 mice ready to go (aged 50-80 human equivalent)

3 – 6 month lead time on another 1000 mice (aged 50-80 human equivalent)

6 – 12 month lead time on further 1000 mice (same age range)

12 – 15 month lead time + 1000 mice

= 4500 mice approx.

At 15 months, if in house breeding is started ASAP, we will have 1000 mice per month available from month 15 onwards

Urgent first 40 studies to test in age 50+ mice

(human equivalent age)

Therapy	Predicted effect	Commercialisability
Gene therapies		
1 x custom GHRH KO	25%	1 year+
1 x custom Prop-1 df	25%	1 year+
6 x custom HTERT AAV9	40%	Immediate
1 x custom PAPP-A KO	25%	1 year+
1 x APOE2 from APOE4 (Alzheimer's)	25% (in APOE4 mice)	1 year+
6 x custom Follistatin AAV9	30%	Immediate
1 x custom FGF21	25%	Immediate
1 x custom PGC1alpha	25%	Immediate
1 x custom SIRT6	25%	Immediate
6 x custom Klotho IV only	30%	Immediate
1 x custom Klotho IV only	20%	Immediate
Other monotherapies		
NAC + Glycine multi-dose	25%	Immediate
Ergothioneine multi-dose	10%	Immediate
20 x Placental Exosomes IVs	20%	Immediate
20 x Placental Stem Cell IVs	20%	Immediate
Thymus Organ Replacement (Ectopic) Age 0	20%	3 years +
1 Kidney replacement with Age 0 Kidney	20%	3 years +
Initial Combos		
Supplement combo (SC)	50%	Immediate
Drug combo (gender specific) (DC)	50%	Immediate
DC + Each Gene Therapy (10 studies)	75%	Mostly Immediate
SC + Each Gene Therapy (10 studies)	75%	Mostly Immediate
All 10 gene therapies	100%	Mostly Immediate

Oliver@20one.consulting

+447851455824

@oliver.Zolman

Contact on WhatsApp

www.oliverzolman.com

www.longevity.school

www.199.clinic London Harley Street

www.3xhelix.com